Voyager Therapeutics prioritizes tau/GBA1/SOD1-ALS pipeline, posts Q2 net loss of $19.1M

Voyager Therapeutics, Inc.

Q2 collaboration revenue $0.7M (down from $1.4M YoY); net loss $19.1M vs $30.1M in Q2 2021.
Prioritized pipeline: tau antibody for Alzheimer's, GBA1 gene therapy for Parkinson's, SOD1 gene silencing for ALS.
Identified receptor for TRACER AAV capsid; AAV9-derived capsid shows 50-60x better brain transduction vs AAV9.
Catherine J. Mackey, Ph.D. (ex-Pfizer) appointed to Board of Directors, effective Aug 15, 2022.
Cash $148.1M expected to fund operations into 2024; Pfizer option decision by Oct 2022, Novartis by Mar 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.